Concepedia

Tom Tang

TT

10

Publications

1.3K

Citations

10

H-Index

2003

Active since

Affiliations

Pfizer (United States)(Current)

Cedars-Sinai Medical Center

University of Florida

University of California San Diego

Western Michigan University

Tom Tang is an author at Pfizer (United States) specializing in medicine, antimicrobial resistance, and clinical microbiology.

ORCID

Top concepts

Publications per year

2003–2023

10

Publications

10

Mitogenic Influence of Human R-Spondin1 on the Intestinal Epithelium

Kyung‐Ah Kim, Makoto Kakitani, Jingsong Zhao et al. · Science · 2005 · 580 citations

, , +11

An Open‐Label, Dose‐Escalation Study to Assess the Safety and Efficacy of IL‐22 Agonist F‐652 in Patients With Alcohol‐associated Hepatitis

Juan Pablo Arab, Tejasav S. Sehrawat, Douglas A. Simonetto et al. · Hepatology · 2019 · 194 citations · Full text

Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis

William J. Sandborn, Stephan R. Targan, Vera S. Byers et al. · The American Journal of Gastroenterology · 2012 · 156 citations · Full text

Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine

Tom Tang, Stephan R. Targan, Z.-S. Li et al. · Alimentary Pharmacology & Therapeutics · 2010 · 121 citations

Human Crossveinless-2 is a novel inhibitor of bone morphogenetic proteins

Minke E. Binnerts, Xiaohui Wen, Kirsten Canté-Barrett et al. · Biochemical and Biophysical Research Communications · 2004 · 77 citations

, , +8

Rows per page

1–5 of 10